1. Scrip
  2. >>Business
  3. >>Strategy

Cash-Strapped DBV Gets FDA Boost For Peanut Allergy Patch

 
• By Kevin Grogan

The French group says it can only fund operations in the first quarter of 2025 but having secured “a clear and reasonable pathway towards an accelerated approval” after talks with the US Food and Drug Administration for its Viaskin Peanut patch in toddlers, the future is looking much brighter.

Peanuts
• Source: Shutterstock

Just a month after expressing “substantial doubt regarding its ability to continue as a going concern,” DBV Technologies shares are soaring on the news that the French firm has reached agreement with regulators in the US to advance a late-stage study in peanut-allergic toddlers.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Biotech Leaders Ponder Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

Novartis $23bn US Investment Is Music To Trump’s Ears

 
• By Kevin Grogan

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

More from Financing

AIRNA To Take RNA Editing Into The Clinic With $155m Series B Round

 
• By Mandy Jackson

CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.

Isomorphic Adds To Growing AI War Chest With First External Funding Round

 
• By Alaric DeArment

The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.

Finance Watch: European And Japanese Biotechs See VC Investor Interest In March

 
• By Mandy Jackson

Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.